Horizon Therapeutics' (HZNP) KOL Call Shows Tepezza Use Broadening Among Clinicians - Jefferies
Tweet Send to a Friend
Jefferies analyst David Steinberg reiterated a Buy rating and $120.00 price target on Horizon Therapeutics (NASDAQ: HZNP) after hosting a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
